- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01781715
Multivessel Stenting Versus Staged Revascularization With Zotarolimus-eluting Stent for STEMI (ZES for STEMI)
30. januar 2013 oppdatert av: Dr. Vladimir Ganyukov, Russian Academy of Medical Sciences
Multivessel Stenting and Staged Revascularization for ST-elevation Myocardial Infarction Patients With Resolute Integrity Stents
The purpose of this study is to determine outcomes (death, myocardial infarction, target vessel revascularization (TVR), non-target vessel revascularization (non-TVR), stent-thrombosis) of 120 consecutive patients with ST elevation myocardial infarction and multivessel coronary artery disease undergoing multivessel stenting or staged percutaneous coronary intervention with Zotarolimus-eluting stents
Studieoversikt
Status
Ukjent
Intervensjon / Behandling
Detaljert beskrivelse
Multivessel coronary artery disease has been reported to occur in 40 to 67% of ST elevation myocardial infarction (STEMI) patients.
Multivessel coronary artery disease (MVCD) patients, who have experienced STEMI, are at a high risk of major cardiovascular events (MACE) within one year after primary PCI.
While MACE incidence in patients with one-vessel coronary artery disease is about 14.5%, patients with two- and three-vessel lesions experience MACE in 19.5% and 23.6% of cases, respectively.
The risk of death in a 5-year follow-up increases two-fold in MVCD patients.
This risk can be partly explained by slower recovery of left ventricular function and progression of left ventricular pathological remodeling process after MI.
In addition, the mere presence of MVCD has been shown to be associated with MACE development in the long-term period.
There are several treatment strategies for ST-elevation myocardial infarction (STEMI) patients with MVCD: infarct related artery (IRA)-only percutaneous coronary intervention (PCI), multivessel stenting in the primary PCI setting and staged revascularisation.
The current guidelines for STEMI revascularisation give no definite instructions on the need for concurrent non-IRA intervention in patients with stable haemodynamics.
At present, there are not clinical trials testing the current Zotarolimus-eluting stents (ZES) in STEMI patients with MVCD undergoing primary PCI for different strategies of revascularization.
Studietype
Intervensjonell
Registrering (Forventet)
120
Fase
- Fase 4
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Vladimir Ganyukov, MD, PhD
- Telefonnummer: +79131273905
- E-post: ganyukov@mail.ru
Studer Kontakt Backup
- Navn: Roman Tarasov, MD, PhD
- Telefonnummer: +79235260446
- E-post: roman.tarasov@mail.ru
Studiesteder
-
-
Kemerovo Region
-
Kemerovo, Kemerovo Region, Den russiske føderasjonen, 650002
- Rekruttering
- State Research Institute for Complex Issues of Cardiovascular Diseases
-
Ta kontakt med:
- Vladimir Ganyukov, MD, PhD
- Telefonnummer: +79131273905
- E-post: ganyukov@mail.ru
-
Ta kontakt med:
- Roman Tarasov, MD, PhD
- Telefonnummer: +79235260446
- E-post: roman.tarasov@mail.ru
-
Hovedetterforsker:
- Vladimir Ganyukov, MD, PhD
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
18 år og eldre (Voksen, Eldre voksen)
Tar imot friske frivillige
Nei
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Subject must be at least 18 years of age.
- Subject is able to verbally confirm understandings of risks, benefits of treatment of either multivessel stenting or staged PCI using the zotarolimus-eluting stent (Resolute Integrity™ Stent, Medtronic) and he or she or his or her legally authorized representative provides written informed consent prior to any study related procedure.
- Subject must have significant stenoses (≥ 70%) of two or more than two of coronary arteries and requiring primary PCI for acute ST elevation myocardial infarction (STEMI) within 12hrs
- Target lesion(s) must be located in a native coronary artery with visually estimated diameter of less than 2.5 mm and more than 4.0 mm.
- Target lesion(s) must be amenable for percutaneous coronary intervention
Exclusion Criteria:
- The patient has a known hypersensitivity or contraindication to any of the following medications: Heparin Aspirin Both Clopidogrel and Ticlopidine, Zotarolimus
- Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study.
- An elective surgical procedure is planned that would necessitate interruption of thienopyridines during the first 6 months post enrollment.
- Non-cardiac comorbid conditions are present with life expectancy over 1 year or that may result in protocol non-compliance (per site investigator's medical judgment).
- Acute heart failure Killip III-IV
- ≥ 50% left main stenosis
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Multivessel stenting
This group comprises the patients who undergo a one-time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions
|
Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
Andre navn:
|
Aktiv komparator: Staged revascularization
This group comprises the patients who undergo PCI of only the culprit lesion and staged nonculprit PCI at a later date (3-15 days)
|
Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
All death including cardiac and non cardiac death
Tidsramme: 30 days, 6 months and 12 montrhs
|
30 days, 6 months and 12 montrhs
|
Recurrent MI
Tidsramme: 30 days, 6 months and 12 months
|
30 days, 6 months and 12 months
|
Any revascularizations (TLR or TVR)
Tidsramme: 30 days, 6 months and 12 months
|
30 days, 6 months and 12 months
|
Composite rate of all death, any MI and any repeat revascularization
Tidsramme: 30 days, 6 months and 12 months
|
30 days, 6 months and 12 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
stent thrombosis
Tidsramme: 30 days. 6 months and 12 months
|
The incidence of stent thrombosis was assessed throughout the follow-up period, according to the conventional ARC (Academic Research Consortium) classification.
|
30 days. 6 months and 12 months
|
Non-TVR
Tidsramme: 30 days, 6 months and 12 months
|
Any repeat revascularization of non target vessels
|
30 days, 6 months and 12 months
|
Andre resultatmål
Resultatmål |
Tidsramme |
---|---|
Composite rate of all death, any MI and any repeat revascularization
Tidsramme: 30 days, 6 months and 12 months
|
30 days, 6 months and 12 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Samarbeidspartnere
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart
1. september 2011
Primær fullføring (Forventet)
1. desember 2013
Studiet fullført (Forventet)
1. desember 2014
Datoer for studieregistrering
Først innsendt
29. januar 2013
Først innsendt som oppfylte QC-kriteriene
30. januar 2013
Først lagt ut (Anslag)
1. februar 2013
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
1. februar 2013
Siste oppdatering sendt inn som oppfylte QC-kriteriene
30. januar 2013
Sist bekreftet
1. januar 2013
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- Resolute Integrity for STEMI
- ZES for STEMI (Annet stipend/finansieringsnummer: Medtronic)
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på ST Elevation Myocardial Infarction, Multivessel Coronary Artery Disease
-
Kitasato UniversityRekrutteringAterosklerose | Akutt koronarsyndrom | Stabil angina | Koronar; Iskemisk | STEMI - ST-segment Elevation Myocardial Infarction | NSTEMI - Non-ST-Segment Elevation Myocardial InfarctionJapan
-
Capital Medical UniversityFullførtTransradial Approach, Primær PCI, ST-segment Elevation Myocardial InfarctionKina
-
VesalioRekrutteringSegment Elevation Myocardial Infarction (STEMI)Sveits
-
AstraZenecaFullførtHjerteinfarkt | Segment Elevation Myocardial Infarction (STEMI)Australia, Frankrike, Italia, Spania, Storbritannia, Sverige, Tyskland, Ungarn, Danmark, Østerrike, Canada, Nederland, Algerie
-
University of Southern CaliforniaAktiv, ikke rekrutterendeNSTEMI - Ikke-ST Segment Elevation MI | Akutt koronarsyndrom (ACS) | STEMI - ST Elevation Myocardial Infarction (MI) | Ustabil angina (UA)Forente stater
Kliniske studier på Zotarolimus-eluting coronary stent
-
Biotronik AGFullførtKoronararteriesykdomRomania
-
Medtronic VascularFullførtKoronararteriesykdom, autosomal dominant, 1Forente stater
-
Medtronic VascularFullførtKoronararteriesykdomKorea, Republikken, Spania, Australia, Hong Kong, Storbritannia, Singapore, Thailand, Belgia, New Zealand, Sverige, Frankrike, Sveits, Nederland, Italia, Slovakia, Litauen, Østerrike, Malaysia, Bulgaria, Irland, Latvia, Norge, Polen
-
Medical University of ViennaFullført
-
Biotronik FranceUkjent
-
Abbott Medical DevicesAvsluttet
-
Chonnam National University HospitalFullførtMyokardiskemi | Koronararteriesykdom | Koronar sykdomKorea, Republikken
-
Seung-Jung ParkCardioVascular Research Foundation, Korea; Medtronic Korea Co., Ltd.RekrutteringKardiovaskulære sykdommer | Koronararteriesykdom | Arterielle okklusive sykdommer | Perkutan transluminal angioplastikkKorea, Republikken
-
Medtronic VascularFullført